Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

M Mohrmann, S Ansorge, U Schmich, B Schönfeld, M Brandis
Author Information
  1. M Mohrmann: Department of Paediatrics, Albert-Ludwigs-Universität Freiburg, Germany.

Abstract

Ifosfamide (IF) and cyclophosphamide (CP) are highly effective alkylating cytostatic drugs. IF and CP have to be activated through a metabolic step in vivo; numerous metabolites are known. While both IF and its structural isomer CP have severe urotoxic side effects, only IF is also a nephrotoxic drug, causing tubular damage resulting in Fanconi syndrome in some cases. Little information is available regarding the pathogenic mechanism of tubular damage by IF. We used the renal epithelial cell line LLC-PK1, which has many properties of the proximal tubule, in order to investigate the toxicity of IF and CP and of their reactive metabolites 4-hydroxy-IF (4-OH-IF), 4-hydroxy-CP (4-OH-CP), acrolein and chloroacetaldehyde (CAA). Protein content of monolayers, DNA and RNA synthesis were determined by standard techniques (thymidine and uridine incorporation). IF and CP had the lowest toxicities of all compounds tested. Both drugs inhibited thymidine incorporation by about 30% at a concentration of 300 mumol/l after 1 h incubation. 4-OH-IF and 4-OH-CP were significantly more toxic than the parent drugs. Thymidine incorporation, the most sensitive parameter, was reduced by about 70% by 300 mumol/l of either compound. In addition, 4-OH-CP reduced the total protein content of monolayers. 4-OH-IF did not effect protein content and RNA synthesis. Acrolein, the most toxic metabolite tested, reduced all three parameters significantly at concentrations of 50-75 mumol/l after 1 h.(ABSTRACT TRUNCATED AT 250 WORDS)

References

  1. Ren Physiol Biochem. 1993 Nov-Dec;16(6):285-98 [PMID: 7506438]
  2. Biochim Biophys Acta. 1983 Nov 23;735(3):325-30 [PMID: 6639944]
  3. Cancer Treat Rep. 1987 Feb;71(2):127-30 [PMID: 2879626]
  4. Drugs. 1991 Sep;42(3):428-67 [PMID: 1720382]
  5. Cancer Chemother Pharmacol. 1986;18 Suppl 2:S25-8 [PMID: 3815717]
  6. J Clin Oncol. 1991 Dec;9(12):2177-82 [PMID: 1720453]
  7. Cancer Chemother Pharmacol. 1989;24 Suppl 1:S40-4 [PMID: 2503258]
  8. Toxicol Lett. 1982 Dec;14(3-4):143-9 [PMID: 6188240]
  9. Cancer Treat Rev. 1987 Jun;14(2):67-86 [PMID: 3119211]
  10. Cancer Chemother Pharmacol. 1988;22(4):353-5 [PMID: 3168149]
  11. Lancet. 1986 Nov 22;2(8517):1219-20 [PMID: 2877353]
  12. Biochim Biophys Acta. 1971 Jan 1;228(1):235-44 [PMID: 4926029]
  13. Semin Oncol. 1989 Feb;16(1 Suppl 3):2-8 [PMID: 2649983]
  14. Arzneimittelforschung. 1976;26(7):1376-7 [PMID: 1036928]
  15. Teratog Carcinog Mutagen. 1987;7(4):399-409 [PMID: 2888218]
  16. Adv Enzyme Regul. 1986;25:99-122 [PMID: 3028054]
  17. J Biol Chem. 1986 Mar 5;261(7):3252-8 [PMID: 3005286]
  18. Anal Biochem. 1985 Oct;150(1):76-85 [PMID: 3843705]
  19. Am J Physiol. 1989 Jul;257(1 Pt 2):F11-7 [PMID: 2750915]
  20. Experientia. 1976 Apr 15;32(4):501-3 [PMID: 1269661]
  21. Cancer Res. 1982 Mar;42(3):830-7 [PMID: 7059981]
  22. Arzneimittelforschung. 1989 Jun;39(6):704-5 [PMID: 2505783]
  23. Biochim Biophys Acta. 1986 Aug 7;860(1):35-43 [PMID: 3730384]
  24. Cancer Treat Rev. 1985 Mar;12(1):1-47 [PMID: 3896483]
  25. Cancer Chemother Pharmacol. 1989;24 Suppl 1:S13-5 [PMID: 2758566]
  26. Ren Physiol Biochem. 1992 Nov-Dec;15(6):289-301 [PMID: 1282722]
  27. J Cancer Res Clin Oncol. 1984;107(3):195-8 [PMID: 6736107]
  28. Arzneimittelforschung. 1979;29(4):659-61 [PMID: 114192]
  29. J Pediatr. 1990 Aug;117(2 Pt 1):331-5 [PMID: 2166154]
  30. Cancer Res. 1988 Apr 1;48(7):1717-21 [PMID: 3349453]
  31. Cancer Res. 1989 Jan 1;49(1):1-7 [PMID: 2491747]
  32. Cancer Res. 1989 May 1;49(9):2344-50 [PMID: 2706622]
  33. Am J Clin Oncol. 1990 Apr;13(2):148-55 [PMID: 2156418]
  34. Am J Physiol. 1986 Feb;250(2 Pt 1):C314-8 [PMID: 3953784]
  35. Am J Physiol. 1987 Nov;253(5 Pt 1):C633-8 [PMID: 2825529]
  36. J Clin Oncol. 1990 Aug;8(8):1399-401 [PMID: 2380760]
  37. Eur J Cancer Clin Oncol. 1986 Jul;22(7):815-9 [PMID: 3095121]
  38. Arch Dis Child. 1990 Jul;65(7):732-8 [PMID: 2386379]
  39. Toxicol Appl Pharmacol. 1985 Apr;78(2):169-79 [PMID: 2930914]
  40. Am J Physiol. 1986 Mar;250(3 Pt 1):G323-30 [PMID: 2420207]
  41. BMJ. 1989 Jun 10;298(6687):1560-1 [PMID: 2503116]
  42. J Biol Chem. 1982 Jun 25;257(12):6802-8 [PMID: 7085605]
  43. Cancer Res. 1983 Dec;43(12 Pt 1):5815-20 [PMID: 6640533]
  44. J Biol Chem. 1983 Feb 25;258(4):2543-7 [PMID: 6822573]
  45. J Cancer Res Clin Oncol. 1981;100(1):95-104 [PMID: 7240346]
  46. In Vitro. 1976 Oct;12(10):670-7 [PMID: 828141]
  47. Cancer Invest. 1988;6(5):513-32 [PMID: 3063337]
  48. Nature. 1958 Mar 29;181(4613):931 [PMID: 13526741]
  49. Am J Physiol. 1982 Jan;242(1):C94-101 [PMID: 6277200]

MeSH Term

Acetaldehyde
Acrolein
Animals
Cell Line
Cells, Cultured
Cyclophosphamide
DNA
DNA Replication
Epithelial Cells
Epithelium
Ifosfamide
Kidney Tubules, Proximal
RNA
Swine
Thymidine
Uridine

Chemicals

RNA
Acrolein
Cyclophosphamide
DNA
chloroacetaldehyde
Acetaldehyde
Ifosfamide
Thymidine
Uridine

Word Cloud

Created with Highcharts 10.0.0IFCPdrugsmetabolitestubular4-OH-IF4-OH-CPcontentincorporationmumol/lreducedcyclophosphamidedamagerenalmonolayersRNAsynthesisthymidinetested3001hsignificantlytoxicproteinIfosfamidehighlyeffectivealkylatingcytostaticactivatedmetabolicstepvivonumerousknownstructuralisomersevereurotoxicsideeffectsalsonephrotoxicdrugcausingresultingFanconisyndromecasesLittleinformationavailableregardingpathogenicmechanismusedepithelialcelllineLLC-PK1manypropertiesproximaltubuleorderinvestigatetoxicityreactive4-hydroxy-IF4-hydroxy-CPacroleinchloroacetaldehydeCAAProteinDNAdeterminedstandardtechniquesuridinelowesttoxicitiescompoundsinhibited30%concentrationincubationparentThymidinesensitiveparameter70%eithercompoundadditiontotaleffectAcroleinmetabolitethreeparametersconcentrations50-75ABSTRACTTRUNCATEDAT250WORDSToxicityifosfamidecellsculture

Similar Articles

Cited By